The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Jun. 11, 2024

Filed:

Dec. 14, 2018
Applicant:

Juno Therapeutics, Inc., Seattle, WA (US);

Inventors:

Susan Byrne, Seattle, WA (US);

Richard Sullivan, Seattle, WA (US);

Francois Vigneault, Seattle, WA (US);

Assignee:

Juno Therapeutics, Inc., Seattle, WA (US);

Attorney:
Primary Examiner:
Assistant Examiner:
Int. Cl.
CPC ...
C07K 16/18 (2006.01); A61K 47/68 (2017.01); C07K 14/705 (2006.01); C07K 16/28 (2006.01); C07K 16/30 (2006.01); C07K 19/00 (2006.01); C12N 5/0783 (2010.01);
U.S. Cl.
CPC ...
C07K 16/18 (2013.01); A61K 47/6803 (2017.08); A61K 47/6843 (2017.08); C07K 14/70521 (2013.01); C07K 14/70578 (2013.01); C07K 16/2806 (2013.01); C07K 16/2809 (2013.01); C07K 16/2863 (2013.01); C07K 16/30 (2013.01); C12N 5/0636 (2013.01); C07K 2317/21 (2013.01); C07K 2317/31 (2013.01); C07K 2317/34 (2013.01); C07K 2317/622 (2013.01); C07K 2319/02 (2013.01); C07K 2319/03 (2013.01); C07K 2319/33 (2013.01);
Abstract

Provided are CCT5-binding molecules, including anti-CCT5 antibodies and antigen-binding fragments thereof such as heavy chain variable (VH) regions and single-chain antibody fragments, and conjugates comprising the anti-CCT5 binding molecules such as immunoconjugates and antibody-drug conjugates, and chimeric receptors comprising the anti-CCT5 binding molecules such as chimeric antigen receptors (CARs). In some embodiments, the anti-CCT5 antibodies or antigen-binding fragments thereof specifically bind to CCT5. Also provided are genetically engineered cells expressing the CARs or CCT5-binding molecules and uses thereof such as in adoptive cell therapy.


Find Patent Forward Citations

Loading…